Gene expression markers for inflammatory bowel disease
AssigneeGenentech, Inc.
InventorsAlexander R. Abbas, Hilary Clark, Lauri Diehl, Charles Lees, Colin L. Noble, Jack Satsangi
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative of an IBD in the mammalian subject from which the test sample was obtained.
Claims45
A method of diagnosing the presence of an inflammatory bowel disease (IBD) in a mammalian subject, comprising determining that the level of expression of a nucleic acid encoding a polypeptide shown as any one of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68. 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96. 98, 100, 102, 104, 106, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 194, 197, 199, 201, 203, 205, 207, and 230 in a test sample obtained from said subject is higher relative to the level of expression in a control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained.
(canceled)
A method of treating an inflammatory bowel disorder (IBD) in a mammalian subject in need thereof, the method comprising the steps of (a) determining that the level of expression of a nucleic acid encoding a polypeptide shown as any one of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26. 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 194, 197, 199, 201, 203, 205, 207, and 230 in a test sample obtained from said subject is higher relative to the level of expression in a control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained;
- and (b) administering to said subject an effective amount of an IBD therapeutic agent.
(canceled)
Dependencies are inferred from the claim text.